Compounds / GH Axis / Sermorelin

Sermorelin

Sermorelin (GHRH 1-29 Analog)
GH AxisWell ResearchedFDA: Previously FDA-approved (Geref)...WADA: PROHIBITED — Category S2

Overview

Previously FDA-approved (Geref — withdrawn 2008, market decision not safety). Robust human clinical data. Bedtime dosing synergizes with natural nocturnal GH secretion.

Mechanism of Action

First 29 amino acids of endogenous GHRH. Stimulates pituitary GH release via GHRH receptor. Previously FDA-approved (Geref). Most clinically studied GHRH analog. Extensive human safety data.

Pharmacokinetics

Half-life
12 min
Peak (Tmax)
10 min
Cleared
~1 hr

Molecular Profile

Molecular weight
3357.9 Da
CAS number
86168-78-7

Key Research Findings

FDA-approved history; robust human data; bedtime dosing; physiologic GH stimulation.

Published Research

BioDrugs (1999)
Prakash A, Goa KL. Sermorelin: Review of its Use in GH Deficiency
View source

Related GH Axis Compounds

IpamorelinCJC-1295 (No DAC)CJC-1295 (DAC)TesamorelinGHRP-2GHRP-6
Clinical Guidance

Research data is not a treatment plan. If you are considering Sermorelin, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Sermorelin? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals